ASH 2024: MF
The panel moderated by Prithviraj Bose, MD, goes into detail on practical aspects of this agent's use in the clinic.
The expert panel moderated by Dr. Bose looks at noteworthy study work on use of this agent for anemia in myelofibrosis.
Empaneled experts describe their investigations of momelotinib in a continued discussion moderated by Prithviraj Bose, MD.
Advertisement
The expert panel moderated by Prithviraj Bose, MD, tells which research presented at the Meeting they found most exciting.
Esteemed experts provide valuable insights into the evolving myelofibrosis landscape and its implications for patient care.
Key takeaways from the top ASH abstracts in the myelofbrosis space.
Advertisement
A roundtable discussion starts with a conversation about the myelofibrosis treatment landscape.
An expert's insights on the latest advancements in MF treatment presented at the ASH 2024 meeting.
Outcomes for patients with AML and MDS who experience relapse after alloHSCT are poor.
Overall, fedratinib 400 mg daily was a safe MTD for post-HSCT maintenance therapy for participants with MPN.
Discussing current clinical trials iand unmet needs in myelofibrosis.
Findings suggest a potential metabolic benefit of pacritinib, warranting further investigation in myelofibrosis.
The PROMise trial aims to examine the safety and preliminary efficacy of OPN-2853 with ruxolitinib for MF treatment.
Odyssey is an ongoing, open-label, phase 2 study that will assess the benefit of adding luspatercept to momelotinib.
A myelofibrosis cohort showed that tapering to achieve molecular remission helped promote OS after transplant.
At ASH 2024, updated results of the RESTORE trial were presented.
These real-world findings highlight momelotinib as an effective and practical treatment for managing MF in everyday practice
BOREAS is the first global phase 3 study to demonstrate clinical efficacy of a single-agent treatment for r/r myelofibrosis.
John Masarenhas discussed the development of the human telomerase inhibitor imetelstat for the treatment of myelofibrosis.
Improvements in the frequency of transfusions and of anemia symptoms are interventional priorities for myelofibrosis.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.